Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-4,333,885
Closed -$33.9M 55
2024
Q4
$33.9M Sell
4,333,885
-2,477,746
-36% -$20.4M 1.15% 21
2024
Q3
$50.4M Sell
6,811,631
-756,848
-10% -$6.36M 1.47% 22
2024
Q2
$60.6M Buy
7,568,479
+3,521,125
+87% +$31.4M 1.7% 19
2024
Q1
$47.1M Hold
4,047,354
1.3% 23
2023
Q4
$45.2M Buy
4,047,354
+2,201,200
+119% +$20.2M 1.13% 23
2023
Q3
$28.5M Hold
1,846,154
0.77% 28
2023
Q2
$35M Hold
1,846,154
0.98% 27
2023
Q1
$28.1M Buy
+1,846,154
New +$24.1M 1.03% 30
2022
Q4
Sell
-3,143,682
Closed -$18.2M 79
2022
Q3
$18.2M Sell
3,143,682
-754,318
-19% -$3.31M 0.75% 41
2022
Q2
$12.6M Buy
+3,898,000
New +$11.8M 0.61% 43

Other funds holding ETNB

BVF Inc's ETNB Position: Q1 2025 in Review

BVF Inc sold out of 89bio (ETNB) in Q1 2025, closing a stake of 4,333,885 shares — an estimated $33.9M sold.

BVF Inc first reported a position in ETNB in Q2 2022 and held it in 10 quarters. The position peaked at $60.6M in Q2 2024. 186 funds tracked by Wall St. Rank hold ETNB as of Q1 2025.

  • BVF Inc reported no remaining 89bio position as of Q1 2025 after selling out during the quarter.
  • BVF Inc sold 4,333,885 89bio shares in Q1 2025, an estimated $33.9M.
  • BVF Inc first reported a position in 89bio in Q2 2022 and held it in 10 quarters.
  • BVF Inc's 89bio position peaked at $60.6M in Q2 2024.
  • 186 funds tracked by Wall St. Rank held 89bio as of Q1 2025.

Based on BVF Inc's 13F filing for Q1 2025, filed 15 May 2025.